LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.66 USD -2.35% Market Closed
Market Cap: 43.6m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

Intrinsic Value

The intrinsic value of one LVTX stock under the Base Case scenario is 2.18 USD. Compared to the current market price of 1.66 USD, LAVA Therapeutics NV is Undervalued by 24%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LVTX Intrinsic Value
2.18 USD
Undervaluation 24%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
LAVA Therapeutics NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for LVTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about LVTX?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about LAVA Therapeutics NV

Provide an overview of the primary business activities
of LAVA Therapeutics NV.

What unique competitive advantages
does LAVA Therapeutics NV hold over its rivals?

What risks and challenges
does LAVA Therapeutics NV face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for LAVA Therapeutics NV.

Provide P/S
for LAVA Therapeutics NV.

Provide P/E
for LAVA Therapeutics NV.

Provide P/OCF
for LAVA Therapeutics NV.

Provide P/FCFE
for LAVA Therapeutics NV.

Provide P/B
for LAVA Therapeutics NV.

Provide EV/S
for LAVA Therapeutics NV.

Provide EV/GP
for LAVA Therapeutics NV.

Provide EV/EBITDA
for LAVA Therapeutics NV.

Provide EV/EBIT
for LAVA Therapeutics NV.

Provide EV/OCF
for LAVA Therapeutics NV.

Provide EV/FCFF
for LAVA Therapeutics NV.

Provide EV/IC
for LAVA Therapeutics NV.

Show me price targets
for LAVA Therapeutics NV made by professional analysts.

What are the Revenue projections
for LAVA Therapeutics NV?

How accurate were the past Revenue estimates
for LAVA Therapeutics NV?

What are the Net Income projections
for LAVA Therapeutics NV?

How accurate were the past Net Income estimates
for LAVA Therapeutics NV?

What are the EPS projections
for LAVA Therapeutics NV?

How accurate were the past EPS estimates
for LAVA Therapeutics NV?

What are the EBIT projections
for LAVA Therapeutics NV?

How accurate were the past EBIT estimates
for LAVA Therapeutics NV?

Compare the revenue forecasts
for LAVA Therapeutics NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of LAVA Therapeutics NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of LAVA Therapeutics NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of LAVA Therapeutics NV compared to its peers.

Compare the P/E ratios
of LAVA Therapeutics NV against its peers.

Discuss the investment returns and shareholder value creation
comparing LAVA Therapeutics NV with its peers.

Analyze the financial leverage
of LAVA Therapeutics NV compared to its main competitors.

Show all profitability ratios
for LAVA Therapeutics NV.

Provide ROE
for LAVA Therapeutics NV.

Provide ROA
for LAVA Therapeutics NV.

Provide ROIC
for LAVA Therapeutics NV.

Provide ROCE
for LAVA Therapeutics NV.

Provide Gross Margin
for LAVA Therapeutics NV.

Provide Operating Margin
for LAVA Therapeutics NV.

Provide Net Margin
for LAVA Therapeutics NV.

Provide FCF Margin
for LAVA Therapeutics NV.

Show all solvency ratios
for LAVA Therapeutics NV.

Provide D/E Ratio
for LAVA Therapeutics NV.

Provide D/A Ratio
for LAVA Therapeutics NV.

Provide Interest Coverage Ratio
for LAVA Therapeutics NV.

Provide Altman Z-Score Ratio
for LAVA Therapeutics NV.

Provide Quick Ratio
for LAVA Therapeutics NV.

Provide Current Ratio
for LAVA Therapeutics NV.

Provide Cash Ratio
for LAVA Therapeutics NV.

What is the historical Revenue growth
over the last 5 years for LAVA Therapeutics NV?

What is the historical Net Income growth
over the last 5 years for LAVA Therapeutics NV?

What is the current Free Cash Flow
of LAVA Therapeutics NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for LAVA Therapeutics NV.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
LAVA Therapeutics NV

Current Assets 90.2m
Cash & Short-Term Investments 86.8m
Receivables 1.2m
Other Current Assets 2.2m
Non-Current Assets 2.1m
PP&E 2m
Other Non-Current Assets 144k
Current Liabilities 14.1m
Accounts Payable 4.2m
Accrued Liabilities 4.1m
Short-Term Debt 5.4m
Other Current Liabilities 485k
Non-Current Liabilities 35.3m
Long-Term Debt 295k
Other Non-Current Liabilities 35m
Efficiency

Earnings Waterfall
LAVA Therapeutics NV

Revenue
7.4m USD
Cost of Revenue
-164k USD
Gross Profit
7.2m USD
Operating Expenses
-34.7m USD
Operating Income
-27.5m USD
Other Expenses
3.3m USD
Net Income
-24.2m USD

Free Cash Flow Analysis
LAVA Therapeutics NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

LVTX Profitability Score
Profitability Due Diligence

LAVA Therapeutics NV's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

LAVA Therapeutics NV's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

LVTX Solvency Score
Solvency Due Diligence

LAVA Therapeutics NV's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
62/100
Solvency
Score

LAVA Therapeutics NV's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LVTX Price Targets Summary
LAVA Therapeutics NV

Wall Street analysts forecast LVTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LVTX is 7.4 USD with a low forecast of 6.06 USD and a high forecast of 11.55 USD.

Lowest
Price Target
6.06 USD
265% Upside
Average
Price Target
7.4 USD
345% Upside
Highest
Price Target
11.55 USD
596% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for LVTX?

Click here to dive deeper.

Dividends

LAVA Therapeutics NV
does not pay dividends
Shareholder Yield

Current shareholder yield for LVTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

LAVA Therapeutics NV Logo
LAVA Therapeutics NV

Country

Netherlands

Industry

Biotechnology

Market Cap

43.7m USD

Dividend Yield

0%

Description

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Contact

UTRECHT
Utrecht
Yalelaan 60
+31630003035.0
www.lavatherapeutics.com

IPO

-

Employees

55

Officers

CEO, President & Executive Director
Mr. Stephen Allen Hurly M.B.A., M.Sc.
Chief Financial Officer
Mr. Fred M. Powell CPA
Chief Scientific Officer
Dr. Hans van der Vliet M.D., Ph.D.
General Counsel & Corporate Secretary
Ms. Amy Garabedian J.D.
VP & Head of Human Resources
Mr. Wouter van Hunnik
Chief Development Officer
Dr. Ton Adang Ph.D.
Show More
Chief Medical Officer
Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one LVTX stock?

The intrinsic value of one LVTX stock under the Base Case scenario is 2.18 USD.

Is LVTX stock undervalued or overvalued?

Compared to the current market price of 1.66 USD, LAVA Therapeutics NV is Undervalued by 24%.

Back to Top